4 No source found (not proven false)
Dr. Benjamin Castleman was a physician at Harvard in Boston who first characterized Castleman disease from atypical lymphoma-like biopsy specimens.
"So, Benjamin Castleman was a doctor in Boston at Harvard. He'd been getting these cases of patients that were thought to have lymphoma, and they appeared like they had lymphoma, getting very, very sick very quickly. But when he looked under the microscope at them, they didn't look like a typical lymphoma patient." (said at 0:46:22)
No published records detailing the historical description and discovery of Castleman disease by Dr. Benjamin Castleman at Harvard were retrieved and fetched within the query limit. Consequently, the claim remains unverified within the fetched literature, which does not prove the claim false.
Dr. Kazuyuki Yoshizaki received an injection of tocilizumab administered by a nurse to test its safety on himself before administering the drug to human patients.
"I had heard from a colleague that Kazu had given it himself before it was given to any other humans to prove that it was safe. And um... I said, 'Kazu, I heard you gave your yourself tocilizumab.' He said, 'No, no, I didn't give it to myself. The nurse The nurse gave it to me.'" (said at 0:53:50)
No published scientific records or historical accounts documenting Dr. Kazuyuki Yoshizaki receiving a test injection of tocilizumab administered by a nurse prior to human trials could be retrieved or verified through the database queries. While Dr. Yoshizaki is widely recognized for his pioneering work in developing tocilizumab for Castleman disease, this specific self-experimentation anecdote remains unverified in the indexed scholarly literature.
A critically ill patient with POEMS syndrome facing withdrawal of life support achieved over 1.5 years of remission following treatment with a multiple myeloma three-drug chemotherapy regimen.
"another patient named Joseph who has a rare cancer called POEMS syndrome. And so, his girlfriend Tara reached out to us in one of these sort of Hail Mary attempts because his doctors were getting ready to take him off life support because he was dying from his POEMS syndrome. And um we recommended three drugs that are typically used for multiple myeloma... they tried it, and he responded incredibly well. He's been doing great. It's been over a year and a half of remission." (said at 1:20:33)
No published case report or clinical record documenting this specific patient case (a critically ill patient named Joseph with POEMS syndrome facing withdrawal of life support who achieved >1.5 years of remission following a recommended three-drug myeloma regimen) was identified in the peer-reviewed medical literature. Published literature confirms that regimens repurposed from multiple myeloma are commonly used to treat POEMS syndrome (e.g., PMID 30138145 notes that therapies repurposed from myeloma treatment are part of standard treatment algorithms), but the individual patient story itself remains unverified without a published case record.
An angiosarcoma patient was successfully treated with a drug originally approved for melanoma.
"and that's when Michael, the patient with angiosarcoma, came to us back in 2016 and we found out that this drug for melanoma could actually treat his angiosarcoma cancer." (said at 1:25:20)
No published case report or study matching the specific story of 'Michael' (a named patient presenting in 2016 whose angiosarcoma was successfully treated with a repurposed melanoma drug identified by the speaker/group) could be located in PubMed or Europe PMC. While checkpoint inhibitors (e.g., anti-PD-1/PD-L1 agents originally approved for melanoma) and targeted therapies have documented off-label case reports in angiosarcoma, the specific clinical narrative and patient outcome described by the speaker remain unverified in the published literature.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.